German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

Despite a net loss, BioNTech SE (BNTX) remains focused on oncology advancements and maintains a strong financial position ...

German drugmaker BioNTech reported Monday wider net loss in its first quarter with weak revenues. Further, the company ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

German biotech BioNTech (Nasdaq: BNTX) saw its shares dip 3.4% to $101.44 today, after it reported financial results for the ...

Conference call and webcast scheduled for May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST) MAINZ, Germany, May 5, 2025 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company ...

May 5 (Reuters) - German COVID-19 vaccine maker BioNTech (22UAy.DE), opens new tab said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1. Zapata-Gomez is currently ...